The concept of the development of S3 guidelines

被引:0
作者
Pfennig, A. [1 ]
Kopp, I. [2 ]
Strech, D. [3 ]
Bauer, M. [1 ]
机构
[1] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Klin & Poliklin Psychiat & Psychotherapie, D-01307 Dresden, Germany
[2] AWMF, Inst Med Wissensmanagement, Marburg, Germany
[3] Med Hsch, Inst Geschichte Eth & Philosophie Med, Hannover, Germany
来源
NERVENARZT | 2010年 / 81卷 / 09期
关键词
Psychiatry; Guidelines; Quality; Consensus; Evidence-based medicine; PHARMACEUTICAL-INDUSTRY; CONTROLLED-TRIALS; QUALITY; METAANALYSIS; PUBLICATION;
D O I
10.1007/s00115-010-3085-6
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Guidelines for the diagnosis and treatment of psychiatric disorders developed on the highest qualitative methodical standard cover reliable decision guidance and are an important instrument of quality improvement in health care. They have to be accessible with little effort and should be concise and clearly presented to be used in daily routine. Early integration of members of the different professions, patients and their care givers into the development process is essential for acceptance. The development process of a S3 guideline is complex and poses a difficult challenge to personal manpower and funding, which is met by the associations of the Association of Medical Societies in Germany. Further scientific discussion is necessary to find adequate solutions for problematic topics or potential distortion, such as the consequences of inadequate reporting of studies, insufficient recording and reporting of the risk of damage, unpublished data and lacking interest of sponsors in specific topics.
引用
收藏
页码:1079 / 1084
页数:6
相关论文
共 26 条
  • [1] The revised CONSORT statement for reporting randomized trials: Explanation and elaboration
    Altman, DG
    Schulz, KF
    Moher, D
    Egger, M
    Davidoff, F
    Elbourne, D
    Gotzsche, PC
    Lang, T
    [J]. ANNALS OF INTERNAL MEDICINE, 2001, 134 (08) : 663 - 694
  • [2] Atkins D, 2004, BMJ-BRIT MED J, V328, P1490
  • [3] *AWMF, 2005, DTSCH INSTR METH LEI
  • [4] *AWMF, 2001, LEITL MAN AWMF AZO
  • [5] *AWML, 2010, EMPF AWMF UMG INT FA
  • [6] AHRQ Series Paper 4: Assessing harms when comparing medical interventions: AHRQ and the Effective Health-Care Program
    Chou, Roger
    Aronson, Naomi
    Atkins, David
    Ismaila, Afisi S.
    Santaguida, Pasqualina
    Smith, David H.
    Whitlock, Evelyn
    Wilt, Timothy J.
    Moher, David
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2010, 63 (05) : 502 - 512
  • [7] Relationship between quality of reports of antidepressant randomized controlled trials and treatment estimates - Systematic review, meta-analysis, and meta-regression analysis
    Cipriani, Andrea
    Malvini, Lara
    Furukawa, Toshiaki A.
    Barbui, Corrado
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2007, 27 (04) : 352 - 356
  • [8] Developing valid guidelines: Methodological and procedural issues from the North of England Evidence Based Guideline Development Project
    Eccles, M
    Clapp, Z
    Grimshaw, J
    Adams, PC
    Higgins, B
    Purves, I
    Russell, I
    [J]. QUALITY IN HEALTH CARE, 1996, 5 (01): : 44 - 50
  • [9] Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies?
    Golder, Su
    Loke, Yoon K.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 66 (06) : 767 - 773
  • [10] Clinical experts or methodologists to write clinical guidelines?
    Hirsh, Jack
    Guyatt, Gordon
    [J]. LANCET, 2009, 374 (9686) : 273 - 275